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1 The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China, 2 BGI College & Henan
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The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China, 4 Department
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Background: MicroRNA-497 (miR-497) has been implicated in several cancers.
Increasing studies demonstrate the role of AKT2 in cancers as an oncogene which
is closely associated with tumor aggressiveness by enhancing cancer cell survival,
migration and invasion However, miR-497/AKT2 axis in non-small cell lung cancer
(NSCLC) remains unclear.
Methods: Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of
miR-497 and its target gene. The function of miR-497 in lung cancer was investigated
through in vitro and in vivo assays (cell proliferation assay, cell migration assay, colony
formation assay, flow cytometry assay, immunoblotting and tumorigenesis assay).
Luciferase reporter assay was conducted to confirm the target gene of miR-497.
Results: In this study, we found that miR-497 was significantly downregulated in
tumor tissues and blood samples of lung cancer patients. To understand the potential
mechanism of miR-497 in inhibiting tumor growth, we showed that miR-497 blocked the
activation of AKT2 and regulated cell proliferation, cell migration, colony formation and
increases chemosensitivity of H1299 cells to cisplatin by inhibiting AKT2. MiR-497 also
inhibited tumor growth and suppressed expression of AKT2 at the protein and mRNA
levels in mouse xenograft tumors.
Conclusion: Taken together, our findings indicated that miR-497 suppresses the tumor
growth by targeting AKT2, and the miR-497/AKT2 axis is a potential therapeutic target
for NSCLC intervention.
Keywords: miR-497, AKT2, tumor growth, chemoresistance, NSCLC
Abbreviations: AKT2, v-AKT murine thym‘oma viral oncogene homolog 2; 3,-UTR: 3, untranslated region; PI3K/AKT,
phosphoinositide 3-kinase/serine/threonine kinase 1; HIF-1α, hypoxia-inducible factor-1α; MiR-497, microRNA-497;
NSCLC, non-small cell lung cancer; SPF: special pathogen-free.
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INTRODUCTION
Lung cancer in the world is the leading cause of cancer-related
mortality, much progress has been made in the treatment of
lung cancer in the past several years. Non-small cell lung cancer
(NSCLC) accounts for approximately 85% of lung cancer cases
(Molina et al., 2008). Cisplatin (CDDP)-based chemotherapy
is widely used as the first-line chemotherapeutic agent for
advanced NSCLC (Scagliotti et al., 2008; Tsai et al., 2011).
However, patients can acquire resistance to CDDP treatment
in 6 months to 1 years, the mechanisms underlying NSCLC
and chemoresistance remain unknown. Better investigation
of the underlying mechanisms in tumor development and
chemoresistance in NSCLC would be indispensable in promoting
prevention, clinical diagnosis and treatment.
MicroRNAs are a group of small 19–25 nucleotides (∼22 nt)
non-coding regulatory RNA molecules (Calin and Croce, 2006;
Liu et al., 2011; Xu et al., 2012). Recently, microRNAs have been
implied in major cellular pathways to regulate cell differentiation,
proliferation, survival and tumorigenesis (Pasquinelli, 2012; Xu
et al., 2013; Jiang et al., 2018; Lin et al., 2019). MiR-497
downregulation has been known in various cancer, which is
associated with tumor growth. Current known miR-497 targets
are CCNE1, VEGFA, Bcl2, KSR1, HDGF and HIF1α, which are
involved in tumorigenesis of various cancers (Han et al., 2015;
Wei et al., 2015; Qiu et al., 2016; Wang et al., 2016; Wu D. et al.,
2016; Wu Z. et al., 2016). However, role of miR-497 in lung cancer
is still unclear.
AKT2, an isoform of AKT family, is reported to be a significant
member of PI3K/AKT pathway (Cheng et al., 1992; Nicholson
and Anderson, 2002). Recent studies demonstrated that AKT2
is an oncogene associated with tumor aggressiveness through
promoting cancer cell survival and invasion (Arboleda et al.,
2003; Cheng et al., 2007). In this study, AKT2 oncogene has
been validated as a novel target of miR-497. Here we also showed
that miR-497 inhibited cell proliferation, cell migration, colony
formation and chemoresistance via its target AKT2 expression.
In this study, we would address following questions: (a)
whether miR-497 expression associated with lung cancer
incidence; (b) what a new target of miR-497 is involved in lung
cancer; (c) what is the underlying role of miR-497 in tumor
growth; and (d) whether miR-497 induce chemosensitivity to
CDDP treatment in lung cancer. This study will questions to
classify the roles and mechanisms of miR-497 in lung cancer
tumorigenesis, be useful for developing new miR-497/AKT2 -
based prognostic marker or/and treatment option.
MATERIALS AND METHODS
Human Clinical Specimens
Cancer tissues and adjacent normal tissues were collected from
lung cancer patients undergoing surgical procedure. Parts of
the samples were fixed in formalin for histological examination,
and parts were immediately snap-frozen in liquid nitrogen. All
clinical samples were histologically classified and de-identified
based on diagnosis using the CoPath Anatomic Pathology system.
No patient information regulated by HIPPA was available for this
study. Experiment protocols have been approved by the Ethics
Committees of Zhengzhou University.
Human blood samples (No patient information regulated by
HIPPA were available for this study) were collected from Henan
Cancer Hospital and The First Affiliated Hospital of Zhengzhou
University with consent of patients and healthy subjects.
Experiment protocols were approved by Ethics Committees of
Zhengzhou University. Plasma samples were de-identified based
on diagnosis using the CoPath Anatomic Pathology system (no
patient information is available), and isolated from bloods by
centrifuging at 3,500 rpm for 10 min, then 300 µL of plasma
and 900 µL of TRIZol reagent were thoroughly mixed, C. elegans
miR-39 (cel-miR-39) was added to final concentration of 10−5 nM
as spiked-in control. According to the manufactory’s instruction,
RNA were extracted and analyzed by qRT-PCR.
Cell Culture and Stable Cell Line
Establishment
Human lung cancer cells H1299, A549, and H1975 were
cultured in RPMI 1640 medium, and HEK293T were maintained
in DMEM in a 37◦C incubator containing 5% CO2. To
stably overexpress miR-497 in lung cancer cells, following the
manufacturer’s manual, lentivirus carrying miR-497 or negative
control (miR-NC) were packaged with HEK293T cells (Thermo
Fisher Scientific, Huntsville, AL, United States).
Cell Viability Assay
Indicated amount of cells were seeded in 96-well culture plates.
According to the manufacturer’s instruction, CCK8 kit was used
to test the cell viability (Dojindo Laboratories, Japan). Results
were obtained with five replicates per experiment from three
separate experiments.
In vitro Migration Assay
Migration assay were conducted with BD migration chambers
according to manufacturer’s instruction (BD Biosciences,
United Kingdom). Cells (without serum) were seeded in the
upper chamber. Then lower chamber were filled with RPMI
1640 medium (with serum). Experiments were independently
repeated three times.
Colony Formation Assay
Cells were placed in 12-well plates, and medium was replaced
every week. Almost 14 days later, cells were fixed and stained with
crystal violet (Sigma-Aldrich). Visible colonies were counted and
measured. Experiments were independently repeated three times.
Dual-Luciferase Reporter Assay
AKT2 (3’-UTR fragment) was amplified by PCR using Pfu
DNA polymerase from cDNA library of H1299 cells. The PCR
products were inserted into pMIR-REPORTER vector. Wild
type (WT) and mutant (MT) constructs were confirmed by
DNA sequencing. Cells were cultured and co-transfected with
luciferase reporter plasmids, renilla luciferase reporter (internal
control) and equal amounts of miR-NC or miR-497. 24–48 h
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later, dual-luciferase (Firefly and Renilla luciferase) activities
were measured (Promega, WI, United States). Experiments were
independently repeated three times.
RNA Isolation and qRT-PCR Analysis
In accordance with manufacturer’s instruction, total RNAs from
human specimens or cultured cells were extracted with TRIzol
reagent (Invitrogen, CA, United States). To quantify AKT2
mRNA levels, oligo dT primer were used for transcription with
RT Kit (Vazyme, China). GAPDH levels were used as an internal
control. To measure expression levels of miR-497, stem-loop RT
primers were used for transcription with RT Kit (Vazyme, China).
SYBR Green Mix (Vazyme, China) was used for qRT-PCR on a
7900HT system. U6 levels were used as an internal control.
Immunoblotting
Human tissues or cells lysates were harvested with RIPA buffer,
then centrifugated at 12,000 rpm for 20 min, and supernatants
were collected. SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) were used for Immunoblotting. The gels were transferred
onto nitrocellulose membranes with transfer buffer. 5% non-fat
dry milk were used to block membranes, and then incubated with
primary antibodies against AKT2 (Proteintech, United States),
GAPDH (Bioworlde, Atlanta, United States). ECL Detection
System was used for signal detection (Thermo Scientific,
Rockford, IL, United States).
In vitro Chemosensitivity Array
5,000 cells were seeded per well in a 96-well plate for 24 h. Then,
freshly prepared CDDP (Sigma-Aldrich, United States) was
added into medium, finally to obtain indicated concentrations
(2.5, 5, 10, 20, 40, 80 to 160 µM). 48 h later, CCK8 kit was
used to value the cell viability. Experiments were independently
repeated three times.
Apoptosis Assay
Apoptosis assay was measured by Annexin V staining. Flow
cytometry (FACS Canto II, BD Biosciences) was used for analysis
of cell apoptosis rate. The data were analyzed using FlowJo
software. Experiments were independently repeated three times.
Caspase-3 Activity Assay
Caspase-3 activity was determined with caspase-3 activity
kit (Beyotime, China). According to the manufacturer’s
protocol, cell lysates after treatment were harvested and
incubated with reaction buffer which containing Ac-DEVD-
pNA (caspase-3 substrate). Absorbance at 405 nm was used to
measure the reaction.
Xenograft Studies
Female nude mice (BALB/cA-nu) were purchased from
Laboratory Animal Center (Shanghai, China), and maintained
FIGURE 1 | Down-regulation of miR-497 expression in tumor tissues of human lung cancer patients. (A) Expression levels of miR-497 in 56 pairs of lung cancer
tumor and adjacent normal specimens were analyzed by stem-loop qRT-PCR, and normalized to the levels of U6. The fold changes were obtained by the ratio of
miR-497 abundance in cancer tissues to that in the adjacent normal tissues. (B) Relative expression levels of miR-497 in different stages of cancer tissues. (C)
qRT-PCR analysis of miR-497 expression in 56 pairs of primary NSCLC tissues and their corresponding lymph node metastases. (D) miR-497 expression was
decreased in plasma of NSCLC patients. The relative expression levels of miR-497 were detected and normalized to the spiked-in control cel-miR-39 (spiked-in
control). Data were presented by mean ± SD. of 3 replicates. *indicated P < 0.05, ** indicated P < 0.01.
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in SPF (special pathogen-free) conditions. For tumor growth
assay, protocols were approved by Animal Welfare Committee
of Zhengzhou University. 5 × 106 cells were injected into
posterior flank of nude mice. Tumor when they were visible
was measured using vernier caliper every two days, and
tumor volume was calculated according to the formula
(volume = 0.5× Length×Width2).
Statistical Analysis
Data were performed as means ± SD of 3 independent
experiments. Student’s unpaired t test in this study was used for
comparison of 2 independent groups. Correlations between miR-
497 and AKT2 levels in human NSCLC tissues were analyzed by
Pearson’s rank test. Values were considered significantly different
at P < 0.05.
RESULTS
Down-Regulation of miR-497 Expression
in Human Blood Samples and Lung
Cancer Tissues
In this study, we tested the expression levels of miR-497 in
56 pairs of NSCLC and normal tissues, which as showed in
Figure 1A that expression levels of miR-497 in NSCLC tissues
were significantly lower than normal tissues. Moreover, miR-
497 expression levels were significantly lower in Grade III-IV
tissues compared with those in Grade I/II, which indicating
that miR-497 was significantly down-regulated in late stages
of lung cancer (Figure 1B). Interestingly, when 56 NSCLC
samples were classified on the basis of the status of lymph
node, we observed miR-497 were significantly lower in NSCLC
with lymph node spread than those without tissues (Figure 1C).
Human plasma samples showed that miR-497 were markedly
decreased in 46 NSCLC patients compared with 10 healthy
subjects, which suggested that miR-497 expression levels can be
detected in the circulation blood samples as a potential biomarker
(Figure 1D). Taken together, the low expression levels of miR-
497 in blood samples and tumor tissues of NSCLC patients could
be used as a potential new biomarker for the diagnosis and
advancement of NSCLC.
AKT2 Is a Direct Target of miR-497
We searched for the probable targets of miR-497 using the
combination of PicTar, TargetScan, and KeyTar algorithms,
and found that there was a putative miR-497 binding site
in 3′-UTR region of AKT2. To test whether miR-497 targets
AKT2, as indicated in Figure 2A, we respectively cloned
3′-UTR region of AKT2 and the mutated sequences into pMIR-
REPORTER vector. Overexpression of miR-497 significantly
decreased reporter activities by almost 60%, while it did
not affect the mutant reporter luciferase activities, suggesting
FIGURE 2 | AKT2 is a direct target of miR-497. (A) Putative seed-matching sites or mutant sites (red) between miR-497 and 3’-UTR of AKT2. (B) Reporter assay of
miR-497 targeting AKT2. Luciferase activities of reporter constructs containing wild-type (WT) or mutant (MT) 3’-UTR of AKT2 were assayed and normalized to those
of renilla activities (internal control). (C) Suppression of AKT2 protein levels by miR-497. Total proteins were subjected to western blotting and detected for AKT2
expression levels.
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FIGURE 3 | Lung cancer tissues exhibits higher levels of AKT2 which are inversely correlated with miR-497 expression. (A) The expression levels of AKT2 in normal
tissues and human NSCLC specimens were determined by qRT-PCR analysis and fold changes were obtained by the ratios of AKT2 to GAPDH levels. (B) Pearson’s
correlation analysis was used to determine the correlation between the expression levels of AKT2 and miR-497 in human NSCLC specimens. Data were presented
by mean ± SD. of 3 replicates. **indicated P < 0.01.
FIGURE 4 | MiR-497 overexpression suppresses cell proliferation, migration and colony formation of lung cancer cells. (A) Expression levels of miR-497 was
conducted in A549 and H1299 cells. (B) Overexpression of miR-497 decreased cell growth activity. (C) Migration assay of A549 and H1299 cells. The results
showed that overexpression of miR-497 inhibited cell migration. (D) Colony formation was conducted in indicated cells, while the activity of colony formation were
reduced in miR-497 group compared with miR-NC. Data were presented by mean ± SD. of 3 replicates. *indicated P < 0.05, **indicated P < 0.01.
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FIGURE 5 | Overexpression of AKT2 reverses the inhibitory effects of miR-497. (A) The expression of AKT2 was rescued by transfection of pCMV-AKT2 for 48 h. (B)
Overexpression of miR-497 arrested cell proliferation, but this was rescued upon coexpression of exogenous AKT2 in H1299 cells. (C) MiR-497 overexpression
decreased cell migration by its target AKT2 in H1299 cells. (D) Overexpression of AKT2 restored miR-497-inhibited colony formation. Data were presented by
mean ± SD of 3 replicates. *or # indicated P < 0.05. *indicates significant difference compared to control;# indicates significant difference compared to miR-497
treatment plus AKT2.
that the mutation site was the binding regions of miR-
497 and AKT2 3′-UTR (Figure 2B). Immunoblotting showed
that miR-497 overexpression was sufficient to inhibit AKT2
protein expression (Figure 2C and Supplementary Figure S1).
Moreover, inhibition of miR-497 induced AKT2 protein
expression (Figure 2C). These results demonstrated that miR-
497 directly inhibited AKT2 expression by directly targeting
its 3′-UTRs.
Lung Cancer Tissues Exhibits Higher
Levels of AKT2 Associated With miR-497
Downregulation
Then, we investigated AKT2 levels in human cancer tissues, and
higher mRNA levels of AKT2 were found in NSCLC tissues
compared with adjacent non-tumor tissues (Figure 3A). We
further investigated the correlation between AKT2 and miR-497
expression levels in NSCLC tissues. As shown in Figure 3B,
Pearson’s correlation analysis showed that AKT2 levels in NSCLC
samples were negatively correlated with miR-497 expression
levels (Pearson’s correlation r =−0.7547, p < 0.01).
MiR-497 Overexpression Inhibits Cell
Proliferation, Cell Migration and Colony
Formation, Overexpression of AKT2
Reverses the Inhibitory Effects of
miR-497
To further study direct role of miR-497 in lung cancer, we
established stable cell lines (A549 and H1299 cells) with
lentivirus carrying miR-497 or negative control (miR-NC).
The stable cell lines were confirmed by high expression
levels of miR-497 (Figure 4A). CCK8 kit indicated that
miR-497 overexpression significantly reduced cell proliferation
rate 48h after the seeding (Figure 4B and Supplementary
Figure S1). Overexpression of miR-497 also significantly
decreased the activity of cell migration (Figure 4C). Then colony
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FIGURE 6 | MiR-497 sensitizes lung cancer cells to CDDP treatment by suppressing AKT2. (A) H1299 cells stably expressing miR-NC or miR-497 were treated with
different concentrations of CDDP for 48 h, and cell viability was analyzed using CCK-8 assay. (B) H1299 cells stably expressing miR-NC, miR-497, or miR-497 in
combination with AKT2 overexpression were treated with 5 µM of CDDP for indicated time points. Cell viability was analyzed by CCK-8 assay. (C,D) Cell apoptosis
was analyzed by flow cytometry and by caspase-3 assay. Data represent mean ± SD from three replicates. *, # indicates P < 0.05; **indicates P < 0.01, *indicates
P < 0.05 compared to miR-NC control. # indicates P < 0.05 compared to miR-497 and AKT2 overexpression group.
formation assay was conducted in indicated cells, which showed
that miR-497 overexpression reduced the activity of colony
formation (Figure 4D, Supplementary Figure S1). Moreover,
inhibition of miR-497 in H1299 induced cell proliferation
and colony formation activity (Supplementary Figure S2).
These results indicated that the miR-497 overexpression is
sufficient to suppress cell proliferation, cell migration and
colony formation.
To explore whether miR-497 exerts its function through
AKT2, H1299 cells were co-transfected with miR-497 or
miR-NC together with pCMV-AKT2 for 48 h (Figure 5A).
Overexpression of AKT2 lacking the miR-497- targeting
3′-UTR rescued the inhibition effect of miR-497 in cell
proliferation and cell migration (Figures 5B,C). Similarly, AKT2
overexpression rescued miR-497-inhibited colony formation
(Figure 5D). These findings suggested that miR-497 inhibits
activity of cell proliferation, cell migration and colony formation
through targeting AKT2.
MiR-497 Sensitizes Lung Cancer Cells to
CDDP Treatment by Suppressing AKT2
Chemoresistance to CDDP is still one of the main causes of drug
resistance in human lung cancer. Thus, it is essential to discover
new strategies to increase CDDP effectiveness. We showed with
H1299 cells as indicated in Figure 6A that forced expression
of miR-497 significantly increased sensitivity to CDDP. Cell
viability rate of 5 µM CDDP treatment were measured by CCK-8
assay at different time points, which showed that overexpression
of AKT2 rendered cancer cells more chemoresistance in miR-
497-overexpressing lung cancer cells (Figure 6B). To deeply
study whether miR-497/AKT2 functioned in cell apoptosis
with CDDP, we conducted apoptosis analysis and caspase-3
assay. Resultly, miR-497 plus CDDP significantly induced cell
apoptosis, overexpression of AKT2 partially abolished the miR-
497-inducing apoptotic effect (Figure 6C). We then showed that
the activity of caspase-3, act as main executor of cell apoptosis,
was significantly increased in miR-497 plus CDDP compared
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FIGURE 7 | MiR-497 inhibits tumorigenesis in vivo. (A,B) Tumor growth assay in nude mice. Tumor growth curve, representative pictures and average weight of
xenograft tumors between the groups of miR-NC and miR-497. Bar: 2 mm. (C) Protein levels of AKT2 in xenograft tumors. (D) The expression levels of AKT2 were
analyzed by qRT-PCR. Data were presented by mean ± SD. of 3 replicates. *indicated P < 0.05; **indicates P < 0.01.
with miR-497 or CDDP treatment alone, overexpression of
AKT2 attenuated caspase-3 induction (Figure 6D). These results
demonstrated that miR-497 renders cancer cells more sensitive
to CDDP, while AKT2 overexpression reversed effect of miR-497
and CDDP in H1299 cells.
MiR-497 Inhibits Tumor Growth in vivo
To investigate the in vivo effect of miR-497, H1299 stable
cell lines were subcutaneously injected into female nude mice
(n = 6). 18 days after post-implantation, tumor volumes of
miR-497 overexpressed group were showed significantly smaller
(Figure 7A). Nude mice were sacrificed on Day 26 after the
injection, and xenografts were collected. Figure 7B showed the
representative xenograft tumors, which indicated that average
tumor weights of miR-497 group was decreased by 70%. Total
RNAs and proteins in tumor samples were analyzed by qRT-
PCR and Immunoblotting, which showed that miR-497 repressed
expression of AKT2 in tumor tissues (Figures 7C,D).
DISCUSSION
Recently, miRNAs are reported to secret into blood system by
normal cells and/or tumor cells, that may be used as biomarkers
(Detassis et al., 2017). Levels of several different miRNAs in
blood are found to be altered in some cancers (Moretti et al.,
2017; Zhou Q. et al., 2018; Zhou X. et al., 2018). MicroRNA-
497 has been reported to inhibit thyroid cancer tumor growth
and invasion by suppressing BDNF (Wang et al., 2017), which
is involved in cell proliferation and invasion of gastric cancer
by repressing eIF4E (Li et al., 2014), and to inhibit colorectal
cancer growth by targeting insulin-like growth factor 1 receptor
(Guo et al., 2013). In this study, we initially showed that miR-497
inhibits cell growth, migration, colony formation; and reverses
chemoresistance in lung cancer cells.
AKT2 was known as an oncogene to promote cancer
development (Jiang et al., 2016). In this study, AKT2 has been
validated as a new target of miR-497 in vitro and in vivo. Higher
mRNA levels of AKT2 were found in NSCLC tissues than non-
tumor tissues with an inverse correlation between AKT2 and
miR-497 expression levels in human tumor samples. This study
firstly provides the evidence that miR-497 is important in abating
lung cancer tumorigenesis through inhibiting AKT2 translation.
Recent studies showed that acquired drug resistance in cancer
cells might be regulated by alterations in miRNA levels (Hummel
et al., 2010; Ma et al., 2010; Zheng et al., 2010; Ge et al., 2018).
We have demonstrated that miR-143 inhibits tumor growth of
colorectal cancer and angiogenesis (Qian et al., 2013), which
makes cells more chemosensitivity to oxaliplatin treatment,
and miR-218 repression contributes to progression of EMT
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(epithelial-mesenchymal transition), chemoresistance and tumor
metastasis by targeting Slug/ZEB2 signaling in lung cancer (Shi
et al., 2017). Other study suggested that cell stemness and
chemoresistance via targeting DLK1 (Ma et al., 2017). In this
study, we showed that miR-497 promotes H1299 cells more
sensitive to CDDP, these results indicate that microRNAs play an
important role in chemoresistance.
Alterations of miRNAs functioned in tumorigenesis and
cancer progression including lung cancer (Khoshgoo et al., 2017;
Krentz Gober et al., 2017). Present investigation suggested that
miR-497 acts as a tumor suppressor, negatively regulates AKT2
oncogene via its 3′-UTR. In addition, we demonstrate that
miR-497 sensitizes lung cancer cells to CDDP treatment in an
AKT2-dependent manner. Taken together, we showed that miR-
497/AKT2 may be potential new lung cancer biomarkers, which
would be interesting for further investigation.
CONCLUSION
In summary, this study suggested that miR-497/AKT2 regulatory
axis in lung cancer, which miR-497 negatively regulates AKT2
oncogene expression and functions as a tumor suppressor. MiR-
497 highlighted its role and sensitized lung cancer cells to CDDP
treatment in an AKT2-dependent manner. These findings may
provide potential new biomarkers for lung cancer diagnosis,
prevention and treatment.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Material, further inquiries can be
directed to the corresponding author/s.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Ethics Committees of Zhengzhou University.
The patients/participants provided their written informed
consent to participate in this study. The animal study was
reviewed and approved by Animal Welfare Committee of
Zhengzhou University.
AUTHOR CONTRIBUTIONS
LW, X-BJ, and L-HW designed and performed experiments,
analyzed data, and wrote the manuscript. J-GQ, W-JL, DW,
F-MZ, ML, and L-ZL performed qRT-PCR assay, reporter
assay and immunoblotting analysis, analyzed chemosensitivity
array and animal analysis. J-YZ and B-HJ supervised the
project. All authors contributed to the article and approved the
submitted version.
FUNDING
This work was supported by National Natural Science
Foundation of China (81803197, U1704188, 81903174, and
81903175) and by National Institutes of Health grants
R01ES027901, and by the Major Project of Science and
Technology in Henan Province (No. 161100311400), and Medical
Science and Technology Project of Henan Province (Nos.
201702298 and 2018020481) and by Key scientific research
projects of universities in Henan Province (No. 18A310010),
Postdoctoral Fund of Henan Province (No. 201902008), and
Science and Technology Research Project of Henan province
(No. 202102310418).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fcell.2020.00840/
full#supplementary-material
REFERENCES
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala,
R., et al. (2003). Overexpression of AKT2/protein kinase Bbeta leads to up-
regulation of beta1 integrins, increased invasion, and metastasis of human
breast and ovarian cancer cells. Cancer Res. 63, 196–206.
Calin, G. A., and Croce, C. M. (2006). MicroRNA signatures in human cancers.
Nat. Rev. Cancer 6, 857–866. doi: 10.1038/nrc1997
Cheng, G. Z., Chan, J., Wang, Q., Zhang, W., Sun, C. D., and Wang, L. H.
(2007). Twist transcriptionally up-regulates AKT2 in breast cancer cells leading
to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67,
1979–1987. doi: 10.1158/0008-5472.can-06-1479
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton,
T. C., et al. (1992). AKT2, a putative oncogene encoding a member of a
subfamily of protein-serine/threonine kinases, is amplified in human ovarian
carcinomas. Proc. Natl. Acad. Sci. U.S.A. 89, 9267–9271. doi: 10.1073/pnas.89.
19.9267
Detassis, S., Grasso, M., Del Vescovo, V., and Denti, M. A. (2017). microRNAs
make the call in cancer personalized medicine. Front. Cell Dev. Biol. 5:86.
doi: 10.3389/fcell.2017.00086
Ge, X., Pan, M. H., Wang, L., Li, W., Jiang, C., He, J., et al. (2018). Hypoxia-
mediated mitochondria apoptosis inhibition induces temozolomide treatment
resistance through miR-26a/Bad/Bax axis. Cell Death Dis. 9:1128.
Guo, S. T., Jiang, C. C., Wang, G. P., Li, Y. P., Wang, C. Y., Guo, X. Y., et al.
(2013). MicroRNA-497 targets insulin-like growth factor 1 receptor and has a
tumour suppressive role in human colorectal cancer. Oncogene 32, 1910–1920.
doi: 10.1038/onc.2012.214
Han, Z., Zhang, Y., Yang, Q., Liu, B., Wu, J., Zhang, Y., et al. (2015). miR-497
and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1).
Oncotarget 6, 13149–13163. doi: 10.18632/oncotarget.3693
Hummel, R., Hussey, D. J., and Haier, J. (2010). MicroRNAs: predictors and
modifiers of chemo- and radiotherapy in different tumour types. Eur. J. Cancer
46, 298–311. doi: 10.1016/j.ejca.2009.10.027
Jiang, C. F., Li, D. M., Shi, Z. M., Wang, L., Liu, M. M., Ge, X., et al. (2016).
Estrogen regulates miRNA expression: implication of estrogen receptor and
miR-124/AKT2 in tumor growth and angiogenesis. Oncotarget 7, 36940–36955.
doi: 10.18632/oncotarget.9230
Jiang, C. F., Shi, Z. M., Li, D. M., Qian, Y. C., Ren, Y., Bai, X. M., et al. (2018).
Estrogen-induced miR-196a elevation promotes tumor growth and metastasis
via targeting SPRED1 in breast cancer. Mol. Cancer 17:83.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 September 2020 | Volume 8 | Article 840
fcell-08-00840 September 6, 2020 Time: 20:45 # 10
Wang et al. MicroRNA-497 Inhibited Tumor Growth
Khoshgoo, N., Visser, R., Falk, L., Day, C. A., Ameis, D., Iwasiow, B. M., et al.
(2017). MicroRNA-200b regulates distal airway development by maintaining
epithelial integrity. Sci. Rep. 7:6382.
Krentz Gober, M., Collard, J. P., Thompson, K., and Black, E. P. (2017).
A microRNA signature of response to erlotinib is descriptive of TGFbeta
behaviour in NSCLC. Sci. Rep. 7:4202.
Li, W., Jin, X., Deng, X., Zhang, G., Zhang, B., and Ma, L. (2014). The putative
tumor suppressor microRNA-497 modulates gastric cancer cell proliferation
and invasion by repressing eIF4E. Biochem. Biophys. Res. Commun. 449, 235–
240. doi: 10.1016/j.bbrc.2014.05.011
Lin, Y., Chen, Z., Zheng, Y., Liu, Y., Gao, J., Lin, S., et al. (2019). MiR-506
targets UHRF1 to inhibit colorectal cancer proliferation and invasion via the
KISS1/PI3K/NF-kappaB signaling axis. Front. Cell Dev. Biol. 7:266. doi: 10.
3389/fcell.2017.00266
Liu, L. Z., Li, C., Chen, Q., Jing, Y., Carpenter, R., Jiang, Y., et al. (2011). MiR-
21 induced angiogenesis through AKT and ERK activation and HIF-1alpha
expression. PLoS One 6:e19139. doi: 10.1371/journal.pone.0019139
Ma, J., Dong, C., and Ji, C. (2010). MicroRNA and drug resistance. Cancer Gene
Ther. 17, 523–531. doi: 10.1038/cgt.2010.18
Ma, Z., Cai, H., Zhang, Y., Chang, L., and Cui, Y. (2017). MiR-129-5p inhibits
non-small cell lung cancer cell stemness and chemoresistance through targeting
DLK1. Biochem. Biophys. Res. Commun. 490, 309–316. doi: 10.1016/j.bbrc.2017.
06.041
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., and Adjei, A. A. (2008). Non-
small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Mayo Clin. Proc. 83, 584–594. doi: 10.4065/83.5.584
Moretti, F., D’antona, P., Finardi, E., Barbetta, M., Dominioni, L., Poli, A., et al.
(2017). Systematic review and critique of circulating miRNAs as biomarkers of
stage I-II non-small cell lung cancer. Oncotarget 8, 94980–94996. doi: 10.18632/
oncotarget.21739
Nicholson, K. M., and Anderson, N. G. (2002). The protein kinase B/Akt signalling
pathway in human malignancy. Cell Signal. 14, 381–395. doi: 10.1016/s0898-
6568(01)00271-6
Pasquinelli, A. E. (2012). MicroRNAs and their targets: recognition, regulation
and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–282. doi:
10.1038/nrg3162
Qian, X., Yu, J., Yin, Y., He, J., Wang, L., Li, Q., et al. (2013). MicroRNA-143 inhibits
tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in
colorectal cancers. Cell Cycle 12, 1385–1394. doi: 10.4161/cc.24477
Qiu, Y., Yu, H., Shi, X., Xu, K., Tang, Q., Liang, B., et al. (2016). microRNA-
497 inhibits invasion and metastasis of colorectal cancer cells by targeting
vascular endothelial growth factor-A. Cell Prolif. 49, 69–78. doi: 10.1111/cpr.
12237
Scagliotti, G. V., Parikh, P., Von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold,
C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage
non-small-cell lung cancer. J. Clin. Oncol. 26, 3543–3551. doi: 10.1200/jco.2007.
15.0375
Shi, Z. M., Wang, L., Shen, H., Jiang, C. F., Ge, X., Li, D. M., et al. (2017).
Downregulation of miR-218 contributes to epithelial-mesenchymal transition
and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene 36, 2577–2588. doi: 10.1038/onc.2016.414
Tsai, C. M., Chen, J. T., Stewart, D. J., Chiu, C. H., Lai, C. L., Hsiao, S. Y.,
et al. (2011). Antagonism between gefitinib and cisplatin in non-small cell
lung cancer cells: why randomized trials failed? J. Thorac. Oncol. 6, 559–568.
doi: 10.1097/jto.0b013e3182021ff5
Wang, L., Jiang, C. F., Li, D. M., Ge, X., Shi, Z. M., Li, C. Y., et al. (2016).
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-
fluorouracil treatment by targeting KSR1. Oncotarget 7, 2660–2671. doi: 10.
18632/oncotarget.6545
Wang, P., Meng, X., Huang, Y., Lv, Z., Liu, J., Wang, G., et al. (2017). MicroRNA-
497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF.
Oncotarget 8, 2825–2834. doi: 10.18632/oncotarget.13747
Wei, C., Luo, Q., Sun, X., Li, D., Song, H., Li, X., et al. (2015). MicroRNA-497
induces cell apoptosis by negatively regulating Bcl-2 protein expression at the
posttranscriptional level in human breast cancer. Int. J. Clin. Exp. Pathol. 8,
7729–7739.
Wu, D., Niu, X., Pan, H., Zhang, Z., Zhou, Y., Qu, P., et al. (2016). MicroRNA-497
targets hepatoma-derived growth factor and suppresses human prostate cancer
cell motility. Mol. Med. Rep. 13, 2287–2292. doi: 10.3892/mmr.2016.4756
Wu, Z., Cai, X., Huang, C., Xu, J., and Liu, A. (2016). miR-497 suppresses
angiogenesis in breast carcinoma by targeting HIF-1alpha. Oncol. Rep. 35,
1696–1702. doi: 10.3892/or.2015.4529
Xu, Q., Jiang, Y., Yin, Y., Li, Q., He, J., Jing, Y., et al. (2013). A regulatory circuit
of miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol. 5, 3–13. doi: 10.1093/
jmcb/mjs049
Xu, Q., Liu, L. Z., Qian, X., Chen, Q., Jiang, Y., Li, D., et al. (2012). MiR-145 directly
targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.
Nucleic Acids Res. 40, 761–774. doi: 10.1093/nar/gkr730
Zheng, T., Wang, J., Chen, X., and Liu, L. (2010). Role of microRNA in anticancer
drug resistance. Int. J. Cancer 126, 2–10. doi: 10.1002/ijc.24782
Zhou, Q., Liu, J., Quan, J., Liu, W., Tan, H., and Li, W. (2018). microRNAs
as potential biomarkers for the diagnosis of glioma: a systematic review and
meta-analysis. Cancer Sci. 109, 2651–2659. doi: 10.1111/cas.13714
Zhou, X., Lu, Z., Wang, T., Huang, Z., Zhu, W., and Miao, Y. (2018). Plasma
miRNAs in diagnosis and prognosis of pancreatic cancer: a miRNA expression
analysis. Gene 673, 181–193. doi: 10.1016/j.gene.2018.06.037
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Wang, Ji, Wang, Qiu, Zhou, Liu, Wan, Lin, Liu, Zhang and Jiang.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 10 September 2020 | Volume 8 | Article 840
